Sagimet Biosciences (STU:0O2) Total Liabilities : €3.69 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Total Liabilities?

Sagimet Biosciences's Total Liabilities for the quarter that ended in Sep. 2024 was €3.69 Mil.

Sagimet Biosciences's quarterly Total Liabilities increased from Mar. 2024 (€4.15 Mil) to Jun. 2024 (€5.32 Mil) but then declined from Jun. 2024 (€5.32 Mil) to Sep. 2024 (€3.69 Mil).

Sagimet Biosciences's annual Total Liabilities increased from Dec. 2021 (€192.30 Mil) to Dec. 2022 (€207.66 Mil) but then declined from Dec. 2022 (€207.66 Mil) to Dec. 2023 (€5.19 Mil).

Sagimet Biosciences Total Liabilities Historical Data

The historical data trend for Sagimet Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Total Liabilities Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

122.83

168.40

192.30

207.66

5.19

Sagimet Biosciences Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial											4.73	5.19	4.15	5.32	3.69

Sagimet Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sagimet Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.185	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	5.19

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	88.691	-	83.507
	=	5.18

Sagimet Biosciences's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.687	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3.69

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	157.472	-	153.785
	=	3.69

Sagimet Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SGMT:USA

Address

155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website

https://www.sagimet.com

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Sagimet Biosciences Headlines

No Headlines